Reviewing DIGILITI MONEY (DGLT) and InVitae Corp (NASDAQ:NVTA)

InVitae Corp (NASDAQ: NVTA) and DIGILITI MONEY (NASDAQ:DGLT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitabiliy, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Earnings and Valuation

This table compares InVitae Corp and DIGILITI MONEY’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
InVitae Corp	$31.43 million	13.92	-$95.64 million	N/A	N/A
DIGILITI MONEY	$9.03 million	0.81	-$6.89 million	N/A	N/A

DIGILITI MONEY has higher revenue, but lower earnings than InVitae Corp.

Insider and Institutional Ownership

4.6% of DIGILITI MONEY shares are owned by institutional investors. 50.9% of DIGILITI MONEY shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares InVitae Corp and DIGILITI MONEY’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InVitae Corp	-260.48%	-119.10%	-76.26%
DIGILITI MONEY	-147.73%	N/A	-199.21%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for InVitae Corp and DIGILITI MONEY, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InVitae Corp	0	0	3	0	3.00
DIGILITI MONEY	0	0	1	0	3.00

InVitae Corp currently has a consensus price target of $14.00, suggesting a potential upside of 35.40%. DIGILITI MONEY has a consensus price target of $6.00, suggesting a potential upside of 711.91%. Given DIGILITI MONEY’s higher probable upside, analysts clearly believe DIGILITI MONEY is more favorable than InVitae Corp.

Summary

DIGILITI MONEY beats InVitae Corp on 6 of the 10 factors compared between the two stocks.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company’s products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

About DIGILITI MONEY

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.